Multiple myeloma

Common Name(s)

Multiple myeloma

Multiple myeloma is a cancer of the plasma cells in the bone marrow. Plasma cells help the body fight infection by producing proteins called antibodies. In multiple myeloma, plasma cells grow out of control in the bone marrow and form tumors in the areas of solid bone. The growth of these bone tumors makes it harder for the bone marrow to make healthy blood cells and platelets. This disease may also harm other tissues and organs, such as the kidneys. Multiple myeloma mainly affects older adults. Although the exact cause is unknown, there are several known risk factors that can increase a person's chance of getting this disease.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Multiple myeloma" for support, advocacy or research.

4th Angel Mentoring Program

Learning that you have cancer can be an overwhelming experience – one that leaves you frightened, vulnerable and alone. The 4th Angel Mentoring Program offers free, one-on-one, confidential outreach and support from someone who has successfully made the same journey you are about to begin – the journey towards recovery. This specially trained volunteer and cancer survivor – your 4th Angel – is someone who will talk and listen in a supportive setting. The 4th Angel Mentoring Program is telephone based, so you can be connect with an angel anywhere in the country. 4th Angel Mentoring Program is part of The Scott Hamilton CARES Initiative, a national non-profit organizat

Last Updated: 12 Dec 2012

View Details
International Myeloma Foundation

To improve the quality of life of myeloma patients while working towards prevention and a cure

Last Updated: 19 Feb 2013

View Details
National Bone Marrow Transplant Link

The mission of the National Bone Marrow Transplant Link is to help patients, caregivers, and families cope with the social and emotional challenges of bone marrow/stem cell transplant from diagnosis through survivorship by providing vital information and personalized support services.

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Multiple myeloma" for support, advocacy or research.

4th Angel Mentoring Program

Learning that you have cancer can be an overwhelming experience – one that leaves you frightened, vulnerable and alone. The 4th Angel Mentoring Program offers free, one-on-one, confidential outreach and support from someone who has successfully made the same journey you are about to begin – the journey towards recovery. This specially trained volunteer and cancer survivor – your 4th Angel – is someone who will talk and listen in a supportive setting. The 4th Angel Mentoring Program is telephone based, so you can be connect with an angel anywhere in the country. 4th Angel Mentoring Program is part of The Scott Hamilton CARES Initiative, a national non-profit organizat

http://www.4thangel.org

Last Updated: 12 Dec 2012

View Details
International Myeloma Foundation

To improve the quality of life of myeloma patients while working towards prevention and a cure

http://www.myeloma.org

Last Updated: 19 Feb 2013

View Details
National Bone Marrow Transplant Link

The mission of the National Bone Marrow Transplant Link is to help patients, caregivers, and families cope with the social and emotional challenges of bone marrow/stem cell transplant from diagnosis through survivorship by providing vital information and personalized support services.

http://www.nbmtlink.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Multiple myeloma" returned 3091 free, full-text research articles on human participants. First 3 results:

Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use.
 

Author(s): Ryan van Laar, Rachel Flinchum, Nathan Brown, Joseph Ramsey, Sam Riccitelli, Christoph Heuck, Bart Barlogie, John D Shaughnessy

Journal:

 

Widespread adoption of genomic technologies in the management of heterogeneous indications, including Multiple Myeloma, has been hindered by concern over variation between published gene expression signatures, difficulty in physician interpretation and the challenge of obtaining sufficient ...

Last Updated: 4 Jun 2014

Go To URL
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.
 

Author(s): Shang-Yi Huang, Chung-Wu Lin, Hsiu-Hsia Lin, Ming Yao, Jih-Luh Tang, Shang-Ju Wu, Yao-Chang Chen, Hsiao-Yun Lu, Hsin-An Hou, Chien-Yuan Chen, Wen-Chien Chou, Woei Tsay, Sheng-Je Chou, Hwei-Fang Tien

Journal: Ann. Hematol.. 2014 Aug;93(8):1371-80.

 

Cereblon (CRBN) is essential for the anti-myeloma (MM) activity of immunomodulatory drugs (IMiDs), such as thalidomide and lenalidomide. However, the clinical implications of CRBN in MM patients are unclear. Using immunohistochemical (IHC) staining on paraffin-embedded bone marrow ...

Last Updated: 4 Jul 2014

Go To URL
Cytotoxicity of graphene oxide and graphene oxide loaded with doxorubicin on human multiple myeloma cells.
 

Author(s): Shaoling Wu, Xindong Zhao, Zhongguang Cui, Chunting Zhao, Yuzhen Wang, Li Du, Yanhui Li

Journal:

 

The purpose of this study was to evaluate the cytotoxicity of human multiple myeloma cells (RPMI-8226) treated with graphene oxide (GO), doxorubicin (DOX), and GO loaded with DOX (GO/DOX). Cell viability was determined using the Cell Counting Kit-8 assay and analyzing the cell cycle ...

Last Updated: 27 Mar 2014

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Multiple myeloma" returned 315 free, full-text review articles on human participants. First 3 results:

Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.
 

Author(s): Andrzej J Jakubowiak

Journal: Cancer Treat. Rev.. 2014 Jul;40(6):781-90.

 

Carfilzomib is a proteasome inhibitor that binds selectively and irreversibly to its target. In July 2012, carfilzomib received accelerated approval in the United States for the treatment of relapsed and refractory multiple myeloma. Based on emerging preclinical data and clinical ...

Last Updated: 13 May 2014

Go To URL
Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients.
 

Author(s): Philip L McCarthy, Theresa Hahn

Journal: Hematology Am Soc Hematol Educ Program. 2013 ;2013():496-503.

 

There have been major advances in the past decade in the continuum of therapy for transplantation-eligible multiple myeloma patients. For patients requiring therapy, recommended induction treatment consists of triple drug regimens followed by the collection of hematopoietic stem cells. ...

Last Updated: 9 Dec 2013

Go To URL
How should we treat newly diagnosed multiple myeloma patients?
 

Author(s): María-Victoria Mateos, Jesús F San Miguel

Journal: Hematology Am Soc Hematol Educ Program. 2013 ;2013():488-95.

 

Multiple myeloma (MM) is the second most frequent hematological disease. Two-thirds of newly diagnosed MM patients are more than 65 years of age. Elsewhere in this issue, McCarthy et al discuss the treatment of transplantation candidates; this chapter focuses on the data available ...

Last Updated: 9 Dec 2013

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

A Phase 1 Study Evaluating CB-5083 in Patients With Relapsed/Refractory Multiple Myeloma
 

Status: Recruiting

Condition Summary: Relapsed Multiple Myeloma; Refractory Multiple Myeloma; Multiple Myeloma

 

Last Updated: 11 Sep 2014

Go to URL
Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma
 

Status: Recruiting

Condition Summary: Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma

 

Last Updated: 30 Apr 2014

Go to URL
Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma
 

Status: Recruiting

Condition Summary: Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma

 

Last Updated: 12 Sep 2014

Go to URL